ABSENCE OF BLOOD FORMATION IN MICE LACKING THE T-CELL LEUKEMIA ONCOPROTEIN TAL-1/SCL

被引:745
|
作者
SHIVDASANI, RA
MAYER, EL
ORKIN, SH
机构
[1] HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115
[2] HOWARD HUGHES MED INST,BOSTON,MA 02115
关键词
D O I
10.1038/373432a0
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
CHROMOSOMAL translocations associated with malignancies often result in deregulated expression of genes encoding transcription factors(1). In human T-cell leukaemias such regulators belong to diverse protein families and may normally be expressed widely (for example, Ttg-1/rbtn1, Ttg-2/rbtn2)(2'3), exclusively outside the haematopoietic system (for example, Hox11)(4), or specifically in haematopoietic cells and other selected sites (for example, tal-1/ SCL, lyl-1)(5,6). Aberrant expression within T cells is thought to interfere with programmes of normal maturation. The most frequently activated gene in acute T-cell leukaemias, tal-1 (also called SCL)(7,8), encodes a candidate regulator of haematopoietic development(9), a basic-helix-loop-helix protein(5), related to critical myogenic(10) and neurogenic(11) factors. Here we show by targeted gene disruption in mice(12) that tal-1 is essential for embryonic blood formation in vivo. With respect to embryonic erythropoiesis, tal-1 deficiency resembles loss of the erythroid transcription factor GATA-(13,14) or the LIM protein rbtn2(15). Profound reduction in myeloid cells cultured in vivo from tal-1 null yolk sacs suggests a broader defect manifest at the myelo-erythroid or multipotential progenitor cell level.
引用
收藏
页码:432 / 434
页数:3
相关论文
共 50 条
  • [21] The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice
    O'Neil, J
    Billa, M
    Oikemus, S
    Kelliher, M
    ONCOGENE, 2001, 20 (29) : 3897 - 3905
  • [22] The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice
    Jennifer O'Neil
    Marilisa Billa
    Sarah Oikemus
    Michelle Kelliher
    Oncogene, 2001, 20 : 3897 - 3905
  • [23] Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase II alpha
    Kelliher, MA
    Seldin, DC
    Leder, P
    EMBO JOURNAL, 1996, 15 (19): : 5160 - 5166
  • [24] THE TRANSLOCATION (1-14)(P34-Q11) IN HUMAN T-CELL LEUKEMIA CHROMOSOME BREAKAGE DOWNSTREAM OF THE TAL-1 ONCOGENE
    XIA, Y
    BROWN, L
    TSOU, TJ
    YINGCHUAN, YC
    SICILIANO, M
    CARROLL, A
    BAER, R
    CYTOGENETICS AND CELL GENETICS, 1991, 58 (3-4): : 1866 - 1866
  • [25] The oncoprotein SCL/Tal-1 associates with the co-repressor ETO-2 in multiprotein complexes in erythroid cells and megalkaryocytes.
    Schuh, AH
    Hamlett, I
    Strouboulis, J
    Grosveld, F
    Vyas, P
    Porcher, C
    BLOOD, 2004, 104 (11) : 759A - 759A
  • [26] Genome-wide transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia.
    Palomero, T
    Odom, DT
    O'Neil, J
    Ferrando, AA
    Winter, SS
    Larson, RS
    Young, RA
    Look, AT
    BLOOD, 2004, 104 (11) : 122A - 122A
  • [27] Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene
    Mikkola, HKA
    Klintman, J
    Yang, HD
    Hock, H
    Schlaeger, TM
    Fujiwara, Y
    Orkin, SH
    NATURE, 2003, 421 (6922) : 547 - 551
  • [28] Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia
    Carlotti, E
    Pettenella, F
    Amaru, R
    Slater, S
    Lister, TA
    Barbui, T
    Basso, G
    Cazzaniga, G
    Rambaldi, A
    Biondi, A
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (04) : 1011 - 1018
  • [29] DISTINCT DNASE-I HYPERSENSITIVE SITES ARE ASSOCIATED WITH TAL-1 TRANSCRIPTION IN ERYTHROID AND T-CELL LINES
    LEROYVIARD, K
    VINIT, MA
    LECOINTE, N
    MATHIEUMAHUL, D
    ROMEO, PH
    BLOOD, 1994, 84 (11) : 3819 - 3827
  • [30] TAL1 Abnormalities in Childhood T-Cell Acute Lymphoblastic Leukemia
    Seki, M.
    Yoshida, K.
    Kimura, S.
    Shiraishi, Y.
    Kato, M.
    Koh, K.
    Hanada, R.
    Deguchi, T.
    Imamura, T.
    Horibe, K.
    Kiyokawa, N.
    Manabe, A.
    Ohara, A.
    Sanada, M.
    Mano, H.
    Hayashi, Y.
    Miyano, S.
    Oka, A.
    Ogawa, S.
    Takita, J.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S117 - S117